{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:16:29Z","timestamp":1770833789537,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vironet C foundation","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>HBeAg is a marker of HBV-activity, and HBeAg-loss predicts a favorable clinical outcome. Here, we characterize HBeAg-levels across different phases of HBV infection, their correlation with virological\/biochemical markers and the virological response to anti-HBV therapy. Quantitative HBeAg (qHBeAg, DiaSorin) is assessed in 101 HBeAg+ patients: 20 with acute-infection, 20 with chronic infection, 32 with chronic hepatitis and 29 with immunosuppression-driven HBV-reactivation (HBV-R). A total of 15\/29 patients with HBV-R are monitored for &gt;12 months after starting TDF\/ETV. qHBeAg is higher in immunosuppression-driven HBV-R (median[IQR]:930[206\u20131945]PEIU\/mL) and declines in chronic hepatitis (481[28\u20131393]PEIU\/mL, p = 0.03), suggesting HBeAg production, modulated by the extent of immunological pressure. This is reinforced by the negative correlation between qHBeAg and ALT in acute infection (Rho = \u22120.66, p = 0.006) and chronic hepatitis (Rho = \u22120.35; p = 0.05). Interestingly, qHBeAg strongly and positively correlates with qHBsAg across the study groups, suggesting cccDNA as a major source of both proteins in the setting of HBeAg positivity (with limited contribution of integrated HBV-DNA to HBsAg production). Focusing on 15 patients with HBV-R starting TDF\/ETV, virological suppression and HBeAg-loss are achieved in 60% and 53.3%. Notably, the combination of qHBeAg &gt; 2000 PEIU\/mL + qHBsAg &gt; 52,000 IU\/mL at HBV-R is the only factor predicting no HBeAg loss (HBeAg loss: 0% with vs. 72.7% without qHBeAg &gt; 2000 PEIU\/mL + qHBsAg &gt; 52,000 IU\/mL, p = 0.03). In conclusion, qHBeAg varies over the natural course of HBV infection, according to the extent of immunological pressure. In the setting of HBV-R, qHBeAg could be useful in predicting the treatment response under immunosuppression.<\/jats:p>","DOI":"10.3390\/biomedicines9101352","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T08:27:44Z","timestamp":1632904064000},"page":"1352","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-0858","authenticated-orcid":false,"given":"Lorenzo","family":"Piermatteo","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0085-8990","authenticated-orcid":false,"given":"Mohammad","family":"Alkhatib","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"D\u2019Anna","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6561-5298","authenticated-orcid":false,"given":"Vincenzo","family":"Malagnino","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, University Hospital of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ada","family":"Bertoli","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"},{"name":"Microbiology and Virology Unit, University Hospital of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Andreassi","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Basile","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Unit, University Hospital of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Iuvara","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Unit, University Hospital of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"De Cristofaro","sequence":"additional","affiliation":[{"name":"Microbiology Unit, \u201cSandro Pertini\u201d Hospital, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Cappiello","sequence":"additional","affiliation":[{"name":"Microbiology Unit, \u201cSandro Pertini\u201d Hospital, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlotta","family":"Cerva","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, University Hospital of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Minichini","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariantonietta","family":"Pisaturo","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Starace","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-4949","authenticated-orcid":false,"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2198-1947","authenticated-orcid":false,"given":"Carla","family":"Fontana","sequence":"additional","affiliation":[{"name":"Microbiology and Virology Unit, University Hospital of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1028-3203","authenticated-orcid":false,"given":"Sandro","family":"Grelli","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"},{"name":"Microbiology and Virology Unit, University Hospital of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Andreoni","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, University Hospital of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Upkar S.","family":"Gill","sequence":"additional","affiliation":[{"name":"Barts Liver Centre, Immunobiology, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick T. F.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Barts Liver Centre, Immunobiology, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1452-0333","authenticated-orcid":false,"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, University Hospital of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Salpini","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Svicher","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"ref_1","unstructured":"WHO (2017). Global Hepatitis Report, 2017, WHO."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/jmv.21645","article-title":"Bioinformatic analysis of the hepadnavirus e-antigen and its precursor identifies remarkable sequence conservation in all orthohepadnaviruses","volume":"82","author":"Revill","year":"2010","journal-title":"J. Med. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.3389\/fmicb.2018.02521","article-title":"Immunomodulatory function of HBeAg related to short-sighted evolution, transmissibility, and clinical manifestation of Hepatitis B virus","volume":"9","author":"Kramvis","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3748\/wjg.v20.i2.425","article-title":"Core promoter: A critical region where the hepatitis B virus makes decisions","volume":"20","author":"Quarleri","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1080\/21645515.2019.1607132","article-title":"Is the function of the HBeAg really unknown?","volume":"15","author":"Milich","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1128\/JVI.79.5.3016-3027.2005","article-title":"Immune Tolerance Split between Hepatitis B Virus Precore and Core Proteins","volume":"79","author":"Chen","year":"2005","journal-title":"J. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14913","DOI":"10.1073\/pnas.0406282101","article-title":"A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen","volume":"101","author":"Chen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3851\/IMP1621","article-title":"The natural history of chronic HBV infection and geographical differences","volume":"15","author":"Liaw","year":"2010","journal-title":"Antivir. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cld.2019.04.002","article-title":"Understanding the Natural History of Hepatitis B Virus Infection and the New Definitions of Cure and the Endpoints of Clinical Trials","volume":"23","author":"Likhitsup","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jvh.13101","article-title":"A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection","volume":"26","author":"Salpini","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_13","first-page":"2323","article-title":"Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B","volume":"91","author":"Hayashi","year":"1996","journal-title":"Am. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"(2000). Heijtink; Janssen; Hop; Osterhaus; Schalm Interferon-alpha therapy in chronic hepatitis B: Early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J. Viral Hepat., 7, 382\u2013386.","DOI":"10.1046\/j.1365-2893.2000.00246.x"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/hep.1840180604","article-title":"Monitoring of antiviral therapy with quantitative evaluation of hbeag: A comparison with HBV DNA testing","volume":"18","author":"Perrillo","year":"1993","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.22065","article-title":"HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B","volume":"47","author":"Fried","year":"2008","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/ajg.2009.371","article-title":"Early HBeAg Loss During Peginterferon \u03b1-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-up Study in Chronic Hepatitis B Patients","volume":"104","author":"Buster","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1478-3231.2006.01418.x","article-title":"Dynamics of hepatitis B e antigen index ratio correlate with treatment response in chronic hepatitis B patients","volume":"27","author":"Wang","year":"2007","journal-title":"Liver Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1590\/S0036-46652009000500005","article-title":"Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B","volume":"51","author":"Pinho","year":"2009","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1365-2893.2005.00602.x","article-title":"Monitoring of HBeAg levels may help to predict the outcomes of lamivudine therapy for HBeAg positive chronic hepatitis B","volume":"12","author":"Park","year":"2005","journal-title":"J. Viral Hepat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.3748\/wjg.v12.i41.6693","article-title":"Clinical significance of hepatitis B e antigen level easurement during long-term lamivudine therapy in chronic hepatitis B patients with e antigen positive","volume":"12","author":"Shin","year":"2006","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"Rnai-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis b virus DNA is a source of hbsag","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Pollicino, T., and Caminiti, G. (2021). HBV-Integration Studies in the Clinic: Role in the Natural History of Infection. Viruses, 13.","DOI":"10.3390\/v13030368"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","article-title":"Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers","volume":"51","author":"Thompson","year":"2010","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/jvh.13453","article-title":"Distinct Hepatitis B and HIV co-infected populations in Canada","volume":"28","author":"Cooper","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Matthews, G.V., Ali, R.J., Avihingsanon, A., Amin, J., Hammond, R., Bowden, S., Lewin, S.R., Sasadeusz, J., Littlejohn, M., and Locarnini, S.L. (2013). Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061297"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1352\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:07:04Z","timestamp":1760166424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/10\/1352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["biomedicines9101352"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9101352","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]}}}